openPR Logo
Press release

Advanced Cancer Pain Management Pipeline Report provides a Therapeutic Assessment of the Key 5+ Pipeline Therapies in this Domain

03-27-2023 07:53 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Advanced Cancer Pain Management Pipeline Report provides

DelveInsight's, "Advanced Cancer Pain Management (ACPM) Pipeline Insights, 2023," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Advanced Cancer Pain Management (ACPM) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For Advanced Cancer Pain Management Emerging drugs, the Advanced Cancer Pain Management pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Advanced Cancer Pain Management pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

In the Advanced Cancer Pain Management Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Advanced Cancer Pain Management clinical trials studies, Advanced Cancer Pain Management NDA approvals (if any), and product development activities comprising the technology, Advanced Cancer Pain Management collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Key takeaways from the Advanced Cancer Pain Management Pipeline Report

• Over 5+ Advanced Cancer Pain Management companies are evaluating 5+ Advanced Cancer Pain Management pipeline therapies in various stages of development, and their anticipated acceptance in the Advanced Cancer Pain Management market would significantly increase market revenue.

• The leading Advanced Cancer Pain Management Companies include Tetra Bio-Pharma, Medlab, Sorrento Therapeutics, Inc., Pfizer, Jazz Pharmaceuticals, Otsuka Pharmaceutical Development & Commercialization, Inc. and others.

• Promising Advanced Cancer Pain Management Pipeline Therapies include Nabiximols, (GA-0034), QIXLEEF, NanaBis, and others.

• The Advanced Cancer Pain Management Companies and academics are working to assess challenges and seek opportunities that could influence Advanced Cancer Pain Management R&D. The Advanced Cancer Pain Management pipeline therapies under development are focused on novel approaches to treat/improve Advanced Cancer Pain Management.

Request a sample and discover the recent breakthroughs happening in the Advanced Cancer Pain Management Pipeline landscape, visit here for Advanced Cancer Pain Management Pipeline Outlook Report @ https://www.delveinsight.com/sample-request/advanced-cancer-pain-management-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Advanced Cancer Pain Management Overview
Advanced Cancer Pain is the pain most commonly experienced and feared by patients with advanced cancer, during their treatment. Pain in a cancer patient is a subjective, multi-dimensional human experience, with complex interactions between sensory and emotional components. Twenty to 34 percent of patients have severe pain, which directly influences their quality of life and daily function (i.e., pain interference). Solid tumors produce more pain than leukemias and lymphomas. Most cancer patients experience pain, usually of moderate to severe intensity, and most also have a number of distinct pains.

Advanced Cancer Pain Management Emerging Drugs Profile

• QIXLEEF: Tetra Bio-Pharma
QIXLEEF™ is a derived medicines developed by Tetra Bio-pharma for the treatment of uncontrolled pain in advanced cancer patients. It is a first-generation, receptor agonists and is derived from a dried flower bud. QIXLEEF™ contains no excipients or other nonmedicinal ingredients. It has a safe and well tolerated profile along with a rapid and high degree of absorption favoring a higher efficacy at a lower dose, compared to oral administration.

• NanaBis: Medlab
NanaBis is the Medlab's based pain management product, comprised of a proprietary 1:1 blend of highly purified and tetrahydrocannabinol (THC) molecules. NanaBis is developed as a pain management alternative to traditional opioids-particularly for patients suffering from advanced types of cancer and chronic pain. In the Phase 1 clinical trial result, it was safe, tolerable, and efficacious and the dosage tolerance was achieved at 60% of the maximum dosage.

For further information, refer to the detailed Advanced Cancer Pain Management Drugs Launch, Advanced Cancer Pain Management Developmental Activities, and Advanced Cancer Pain Management News, click here for Advanced Cancer Pain Management Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/advanced-cancer-pain-management-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Advanced Cancer Pain Management Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for Advanced Cancer Pain Management (ACPM). The companies which have their Advanced Cancer Pain Management (ACPM) drug candidates in the most advanced stage, i.e. phase III include, Tetra Bio-Pharma.

Advanced Cancer Pain Management Pipeline: Phases
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Advanced Cancer Pain Management Pipeline: Route of Administration
• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical

Advanced Cancer Pain Management Pipeline: Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

To find out more about the Advanced Cancer Pain Management Pipeline Segmentation, Therapeutics Assessment, Advanced Cancer Pain Management Emerging Drugs, visit here for Advanced Cancer Pain Management Treatment Landscape @ https://www.delveinsight.com/sample-request/advanced-cancer-pain-management-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Advanced Cancer Pain Management Pipeline Report

• Coverage- Global

• Advanced Cancer Pain Management Companies- Tetra Bio-Pharma, Medlab, Sorrento Therapeutics, Inc., Pfizer, Jazz Pharmaceuticals, Otsuka Pharmaceutical Development & Commercialization, Inc. and others.

• Advanced Cancer Pain Management Pipeline Therapies- Nabiximols, (GA-0034), QIXLEEF, NanaBis, and others.

• Advanced Cancer Pain Management Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Advanced Cancer Pain Management Pipeline Companies and Therapies, click here for Advanced Cancer Pain Management Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/advanced-cancer-pain-management-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Advanced Cancer Pain Management (ACPM): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced Cancer Pain Management (ACPM) - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Advanced Cancer Pain Management (ACPM) Collaboration Deals
9. Late Stage Products (Phase III)
10. QIXLEEF: Tetra Bio-Pharma
11. Early Stage Products (Phase I)
12. NanaBis: Medlab
13. Drug profiles in the detailed report…..
14. Inactive Products
15. Advanced Cancer Pain Management (ACPM) Key Companies
16. Advanced Cancer Pain Management (ACPM) Key Products
17. Advanced Cancer Pain Management (ACPM)- Unmet Needs
18. Advanced Cancer Pain Management (ACPM)- Market Drivers and Barriers
19. Advanced Cancer Pain Management (ACPM)- Future Perspectives and Conclusion
20. Advanced Cancer Pain Management (ACPM) Analyst Views
21. Advanced Cancer Pain Management (ACPM) Key Companies
22. Appendix

Got Queries? Find out the related information on Advanced Cancer Pain Management Mergers and acquisitions, Advanced Cancer Pain Management Licensing Activities, just visit here for Advanced Cancer Pain Management Recent Trends, and Future Perspectives @ https://www.delveinsight.com/sample-request/advanced-cancer-pain-management-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Healthcare Partner Identification Services @ https://www.delveinsight.com/consulting/partner-identification-services

Medical Marijuana Market @ https://www.delveinsight.com/report-store/medical-marijuana-market-insight

Oncolytic Virus Cancer Therapy Pipeline @ https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Overactive Bladder Syndrome Market @ https://www.delveinsight.com/report-store/overactive-bladder-market

Pediatric Growth Hormone Deficiency PGHD Market @ https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market

Percutaneous Arterial Closure Device Market @ https://www.delveinsight.com/report-store/percutaneous-arterial-closure-device-market

Ranibizumab Biosimilars Insight @ https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight

Schistosomiasis Market @ https://www.delveinsight.com/report-store/schistosomiasis-market

Stem Cell Market @ https://www.delveinsight.com/report-store/stem-cell-market

Superficial Punctate Keratitis Market @ https://www.delveinsight.com/report-store/superficial-punctate-keratitis-market

Technical Due Diligence @ https://www.delveinsight.com/consulting/due-diligence-services

Transient Ischemic Attack Market @ https://www.delveinsight.com/report-store/transient-ischemic-attack-market

Wilms Tumor Market @ https://www.delveinsight.com/report-store/wilms-tumor-market

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj

info@delveinsight.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Advanced Cancer Pain Management Pipeline Report provides a Therapeutic Assessment of the Key 5+ Pipeline Therapies in this Domain here

News-ID: 2989508 • Views:

More Releases from DelveInsight Business Research

Endometrial Cancer Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, Abbott Laboratories, Inc., ARIAD Pharmaceuticals
Endometrial Cancer Market to Witness Upsurge in Growth During the Forecast Perio …
The Endometrial Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Endometrial Cancer pipeline products will significantly revolutionize the Endometrial Cancer market dynamics. DelveInsight's "Endometrial Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Endometrial Cancer, historical and forecasted epidemiology as well as the Endometrial Cancer market trends in the United
ESR1 Mutated Metastatic Breast Cancer Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Radius Pharmaceuticals/ Menarini Group, Pfizer, G1 Therapeutics, Sanofi, Sun PharmaAdvanced Research
ESR1 Mutated Metastatic Breast Cancer Market is Expected to Expand at a Healthy …
DelveInsight's "ESR1 Mutated Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the ESR1 Mutated Metastatic Breast Cancer, historical and forecasted epidemiology as well as the ESR1 Mutated Metastatic Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the ESR1 Mutated Metastatic Breast Cancer market outlook, drug uptake, treatment scenario
Giant Cell Arteritis Market to Observe Impressive Growth During the Forecast Period (2024-2034), Evaluates DelveInsight | AbbVie, Novartis, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, Eli Lilly and Company, Roche Pharma
Giant Cell Arteritis Market to Observe Impressive Growth During the Forecast Per …
The Giant Cell Arteritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Giant Cell Arteritis pipeline products will significantly revolutionize the Giant Cell Arteritis market dynamics. DelveInsight's "Giant Cell Arteritis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Giant Cell Arteritis, historical and forecasted epidemiology as well as the Giant Cell Arteritis market
Endometriosis Pain Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences
Endometriosis Pain Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Ap …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Endometriosis Pain pipeline constitutes 5+ key companies continuously working towards developing 5+ Endometriosis Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Endometriosis Pain Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Endometriosis Pain Market. The Endometriosis

All 5 Releases


More Releases for Cancer

Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose. Increase in incidence of target diseases like cancer is key driving factor which is expected to boost
Oncology Nutrition Market led to an unprecedented rise by 2025 : liver cancer, p …
Global Oncology Nutrition Market: Overview Cancer diagnosis creates myriad questions about diet and nutrition. Those pertain to if the food will make a patient feel sick to what should be ingested to fight cancer. This has spawned the oncology nutrition market which has been rising steadily due to the increasing cases of different types of cancer worldwide. During cancer treatment one needs to eat right in order to build up strength
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business. Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine. These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top